Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment

NCT03116152 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

BIOLOGICAL: IBI308
DRUG: paclitaxel/ irinotecan

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.